Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A

As of June 30, 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A carries a market capitalization of 47.59B, placing it among publicly traded companies globally. Its enterprise value stands at 46.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A has 896.23M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A maintains a current ratio of 25.60, meaning it holds 25.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A recorded 424.86M in income tax expense.

As of the close on October 22, 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A's stock has declined approximately 20.93% over the past 52 weeks. The 50-day moving average sits at 41.48, while the 200-day moving average is 44.60.

These figures are as of June 30, 2026. Total book value stands at 8.50B, with working capital of 5.77B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A paid dividends of 0.02 per share.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A's most recent stock split took place on June 18, 2026 with a 20:29 split ratio.